Skip to main content
. 2022 Feb 5;14:23. doi: 10.1186/s13195-022-00961-5

Table 2.

Summary of included studies

First author, publication year Tissue Analysis method N (case/HC) MMSE of case Mean age % Male
Brain GSH studies—AD
Mandal, 2015 [35] Brain: hippocampus, frontal cortex MEGA-PRESS, reference: water 19/28 23.6 66.2 68%
Marjanska, 2019 [32] Brain: posterior cingulate, occipital cortex STEAM, reference: water 16/33 19 73.2 82%
Mullins, 2018 [31] Brain: posteromedial cortex J-PRESS, reference: creatine 27/54 25.4 72.2 57%
Shukla, 2019 Brain: anterior and posterior cingulate MEGA-PRESS, reference: water 18/27 N/A 69.4 70%
Brain GSH studies—MCI
Duffy, 2014 [33] Brain: anterior and posterior cingulate PRESS, reference: creatine 54/41 28.7 68 52%
Mandal, 2015 [35] Brain: hippocampus, frontal cortex MEGA-PRESS, reference: water 22/28 24.2 66 65%
Oeltzschner, 2019 [34] Brain: anterior and posterior cingulate STEAM, reference: creatine 13/26 28.1 69 65%
Shukla, 2019 Brain: anterior and posterior cingulate MEGA-PRESS, reference: water 19/28 N/A 66.6 71%
Blood GSH studies—AD
Arslan, 2016 [36] Erythrocyte DTNB 24/15 N/A 73.5 77%
Aybek, 2007 [37] Serum DTNB 62/56 17.8 72.1 47%
Bai, 2018 [38] Plasma DTNB 16/16 13.1 N/A N/A
Baldeiras, 2008 [39] Plasma and erythrocyte OPA 42/37 20.9 70.8 39%
Bermejo, 2008 [40] Erythrocyte OPA 45/28 N/A 80.0 N/A
Bicikova, 2004 [41] Serum HPLC 21/40 N/A 72.5 44%
Fernandes, 1999 [45] Plasma and erythrocyte OPA 74/35 N/A 67.2 45%
Gironi, 2011 [43] Serum HPLC 25/66 18.9 72.5 36%
Gironi, 2014 [42] Erythrocyte HPLC 37/28 N/A 76.1 40%
Gubandru, 2013 [44] Plasma DTNB 21/10 10.51 79.9 52%
Hernanz, 2007 [46] Plasma HPLC 25/44 N/A 73.4 52%
Kliumiuk, 2019 [47] Plasma DTNB 15/50 13.4 80.9 30%
Kosenko, 2016 [48] Erythrocyte DTNB 12/14 N/A 76.1 35%
Krishnan, 2014 [49] Plasma and erythrocyte DTNB 30/40 4 66.3 54%
Kurup, 2003 [50] Erythrocyte DTNB 15/15 N/A N/A N/A
Liu, 2005 [51] Plasma,erythrocyte, and leukocyte HPLC 33/20 17.7 75.9 45%
Martinez de Toda, 2019 [52] Whole blood OPA 20/30 N/A 55%
McCaddon, 2003 [53] Plasma HPLC 50/57 18 79.0 37%
Mohamed, 2019 [54] Serum ELISA 50/25 19.2 69.8 50%
Prendecki, 2018 [55] Plasma HPLC 88/80 15.3 73.9 73%
Puertas, 2012 [56] Plasma DTNB 46/46 22 74.2 39%
Rani, 2017 [57] Plasma DTNB 45/45 3.5 69.6 N/A
Riveron, 2007 [58] Plasma DTNB 25/30 N/A N/A N/A
Sadhu, 2014 [59] Plasma DTNB 104/93 6.4 N/A 54%
Tabet, 2002 [60] Plasma Commercial Assay Kit 31/30 13.9 N/A 46%
Vida, 2018 [61] Whole blood, neutrophil, lymphocyte OPA 44/38 19.3 75.9 41%
Blood GSH studies—MCI
Baldeiras, 2008 [39] Plasma and erythrocyte OPA 85/37 27 70.3 39%
Bermejo, 2008 [40] Erythrocyte OPA 34/28 27 78.3 N/A
Gironi, 2011 [43] Serum HPLC 20/66 N/A 71.4 33%
Gironi, 2014 [42] Erythrocyte HPLC 26/28 21.5 76.5 43%
Hernanz, 2007 [46] Plasma HPLC 26/44 N/A 74.4 51%
Martinez de Toda, 2019 [52] Whole blood OPA 20/30 25 N/A 50%
Yuan, 2016 [62] Plasma Commercial assay kit 138/138 N/A 64.5 51%

Abbreviations: AD Alzheimer disease, DSM Diagnostic And Statistical Manual of Mental Disorders, DTBN 5,5′-dithio-bis(2-nitrobenzoic acid), ELISA enzyme-linked immunosorbent assay, GSH glutathione, HC healthy control, HPLC high performance liquid chromatography, MCI mild cognitive impairment, MEGA-PRESS Meshcher-Garwood Point-Resolved Spectroscopy, MMSE Mini-Mental State Examination, N/A not available, OPA O-Phthalaldehyde, PRESS Point-Resolved Spectroscopy, SMD standardized mean difference, STEAM STimulated Echo Acquisition Mode